What is the new alternative to opioids? Exploring the First-in-Class Drug Journavx
•
4 min read
After more than two decades without a major breakthrough, the FDA approved Journavx (suzetrigine) in early 2025, introducing the first new class of non-opioid pain medication to the market. This medication is a promising answer to the question, "What is the new alternative to opioids?", offering a safer option for patients dealing with moderate to severe acute pain.
